Validation of the all-comers design: Results of the TARGET-AC substudy.
暂无分享,去创建一个
A. Baumbach | A. Lansky | W. Wijns | S. Brugaletta | E. Barbato | L. Maillard | L. Holmvang | N. van Royen | H. Kelbæk | F. Kiemeneij | A. Milkas | K. Ameloot | C. Naber | L. Janssens | C. Jensen | Gabor G Toth | C. Robles | P. N. Laursen | J. Sévilla | Felix Pucher
[1] A. Íñiguez,et al. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. , 2019, International journal of cardiology.
[2] Fei Ye,et al. Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: The ULTIMATE Trial. , 2018, Journal of the American College of Cardiology.
[3] P. Nakaji,et al. Letter: Enrollment-To-Screening Ratio: An Undervalued Data in Randomized Clinical Trials. , 2018, Neurosurgery.
[4] P. Serruys,et al. Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants. , 2011, European heart journal.
[5] M. Simoons,et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. , 2006, European heart journal.
[6] S D Simon,et al. Is the randomized clinical trial the gold standard of research? , 2001, Journal of andrology.
[7] J. Lewsey,et al. Comparing outcomes of percutaneous transluminal coronary angioplasty with coronary artery bypass grafting; can routine health service data complement and enhance randomized controlled trials? , 1999, European heart journal.
[8] B. Sibbald,et al. Understanding controlled trials: Why are randomised controlled trials important? , 1998 .
[9] N. Sharpe. Clinical Trials and the Real World: Selection Bias and Generalisability of Trial Results , 2004, Cardiovascular Drugs and Therapy.
[10] F. Eberli,et al. revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial , 2022 .